Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 15;11(8):4866-4880.
eCollection 2019.

Expression profile and prognostic values of STAT family members in non-small cell lung cancer

Mengqi Yang  1   2 , Huanting Chen  3 , Lin Zhou  4 , Kai Chen  1   2 , Fengxi Su  1   2
Affiliations

Expression profile and prognostic values of STAT family members in non-small cell lung cancer

Mengqi Yang et al. Am J Transl Res. .

Abstract

Non-small cell lung cancer (NSCLC) is a highly malignant type of cancer with a poor 5-year survival rate. The development of prognostic biomarkers and novel drug targets are required in order to improve the survival for NSCLC patients. Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors known to play key roles in many cellular biological processes. However, the roles of STAT family members in the development and progression of NSCLC have not yet been apparently determined. Our study investigated the roles of STATs in the prognosis of NSCLC using cBioPortal, Human Protein Atlas, ONCOMINE, and Kaplan-Meier Plotter databases. High mutation rate of STATs existed in both lung adenocarcinoma (ADE) patients and squamous cell carcinoma (SCC) patients. High mRNA expression of STAT2 was significantly associated with shorter overall survival (OS) in NSCLC patients, while increased STAT5 and STAT6 were associated with better OS in NSCLC patients. We further found that increased mRNA expressions of STAT2 and STAT3 predicted unfavorable overall survival (OS) while high mRNA expression of STAT5B and STAT6 related to favorable OS for lung ADE patients. However, no significant correlation was identified for lung SCC patients. In stratified survival analysis, high expression of STAT2 predicted poor prognosis in stage II NSLCC patients, surgical margins negative patients and female patients. Taken together, our results illustrated that STAT5B and STAT6 could be effective prognostic biomarkers for survivals of NSCLC patients. And STAT2 might be a promising therapeutic target for the treatment of NSCLC as well as ADE.

Keywords: STAT; non-small cell lung cancer; online database; prognosis; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Genetic alterations of STAT family members in NSCLC. (A, B) Alteration frequency of STATs in lung ADE (A) and SCC (B) via cBioPortal. (C) The FPKM value of each STAT member in NSCLC via HPA.
Figure 2
Figure 2
mRNA expression of distinct STAT members in lung ADE and normal tissues using Oncomine (threshold: p-value = 0.05, 1.5 fold change, top 10% gene rank).
Figure 3
Figure 3
mRNA expression of distinct STAT members in lung SCC and normal tissues using Oncomine (threshold: p-value = 0.05, 1.5 fold change, top 10% gene rank).
Figure 4
Figure 4
Prognostic value of STAT family members in NSCLC patients using Kaplan-Meier plotter.
Figure 5
Figure 5
Prognostic value of mRNA expression of STAT family members in lung ADE patients using Kaplan-Meier plotter.
Figure 6
Figure 6
Prognostic value of mRNA expression of STAT family members in lung SCC patients using Kaplan-Meier plotter.
See this image and copyright information in PMC

References

    1. PDQ cancer information summaries. Bethesda (MD): 2002. Lung Cancer Screening (PDQ(R)): Health Professional Version.
    1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49–52. - PubMed
    1. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, Tan DSW. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17:e347–e362. - PubMed
    1. Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA. Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer. Future Oncol. 2019;15:2943–2953. - PubMed
    1. Berg T. Signal transducers and activators of transcription as targets for small organic molecules. Chembiochem. 2008;9:2039–2044. - PubMed

LinkOut - more resources